Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07062016 · ClinicalTrials.gov registry record

Molecular and ctDNA Characterization of High-Risk Endometrial Cancer

A clinical trial of Endometrial Carcinoma and Stage III Endometrial Cancer, sponsored by Mayo Clinic.

Recruiting
Registry status
100
Enrollment target
1
Study location

NCT07062016: Recruiting study of Endometrial Carcinoma and Stage III Endometrial Cancer, sponsored by Mayo Clinic.

NCT07062016 is a study of Endometrial Carcinoma and Stage III Endometrial Cancer that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 100 participants, below the 387-participant average among 27 other Endometrial Carcinoma trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07062016, a study of Endometrial Carcinoma and Stage III Endometrial Cancer, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

This study seeks to better understand the recurrence of high-risk endometrial cancer. It will collect information about cancer genetics to find out various hereditary or cancer specific genetic variants that may have a role in diagnosis or management and prognosis of cancer. It also seeks to develop a genetic results and medical record databank for future studies.

Primary Outcome

Defined as time from primary staging surgery to recurrence or death.

Interventions

  • OTHER Non-Interventional Study

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-10-01
Est. Completion 2028-10-31
Mayo Clinic

2,844 total trials

What NCT07062016 shows while recruiting

NCT07062016 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 387-participant average among 27 other Endometrial Carcinoma trials with a reported enrollment target (74% lower).

The record links to 5 conditions, with Endometrial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.

NCT07062016 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT07062016 about?

NCT07062016 is a clinical study titled "Molecular and ctDNA Characterization of High-Risk Endometrial Cancer". This study seeks to better understand the recurrence of high-risk endometrial cancer. It will collect information about cancer genetics to find out various hereditary or cancer specific genetic variants that may have a role in diagnosis or management and prognosis of cancer. It also seeks to develop...

What is the current status of trial NCT07062016?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-10-01. Estimated completion is 2028-10-31.

What conditions does trial NCT07062016 study?

This clinical trial studies the following conditions: Endometrial Carcinoma, Stage III Endometrial Cancer, Endometrial High Grade Endometrioid Adenocarcinoma, Stage II Endometrial Cancer, Stage IV Endometrial Cancer.

What interventions are being tested in trial NCT07062016?

The interventions under investigation include: Non-Interventional Study (OTHER).

Who is sponsoring clinical trial NCT07062016?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07062016 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Endometrial Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07062016's enrollment target sits among peer trials

100 12th of 27 higher than 16 of 27 other Endometrial Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Endometrial Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07062016, the US trial registry maintained by the National Library of Medicine. NCT07062016 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.